3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Other solid neoplasm
1
NET
1
Head & Neck
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Breast
1
Conditions
Colorectal Neoplasms
15
Carcinoma, Hepatocellular
8
Neoplasm Metastasis
3
Rectal Neoplasms
2
Melanoma
2
Cholangiocarcinoma
2
Advanced Colorectal Cancer
2
Turcot syndrome
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Tertiary Lymphoid Structures
1
TAS 102
1
Stomach Neoplasms
1
Sarcoma
1
Mesothelioma, Malignant
1
Liver Neoplasms
1
Gastrointestinal Stromal Tumors
1
Gastro-enteropancreatic neuroendocrine tumor
1
Fatigue
1
Colorectal Cancer Metastatic
1
Colorectal Cancer Liver Metastases
1
Colonic Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma
1
Biliary Tract Neoplasms
1
Asian Colorectal Cancer Patients
1
Advanced Colorectal Carcinoma
1
Advanced Biliary Systemic Tumours That Has Failed at Least One Prior Systemic Therapy
1
Interventions
regorafenib
1
copper dotatate CU-64
1
Irinotecan
1
Fluorodeoxyglucose F18
1
Etoposide
1
Copper
1
Clinical Trials, Phase II as Topic
1
Cisplatin
1
64Cu-DOTATATE
1
177Lu-octreotide, DOTA(0)-Tyr(3)-
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Gastro-enteropancreatic neuroendocrine tumor
×
regorafenib
×
Clear all
NCT03475953
2023-03-03
REGOMUNE
Institut Bergonié
Phase 1/2
Unknown
747 enrolled